IMPORTANCE: High serum levels of interleukin 17F (IL-17F) at baseline have been associated with suboptimal response to interferon beta in patients with relapsing-remitting multiple sclerosis. OBJECTIVE: To further investigate the role of IL-17F in predicting treatment response to interferon beta-1b in patients with relapsing-remitting multiple sclerosis using the Singulex Erenna IL-17F immunoassay. DESIGN, SETTING, AND PATIENTS: Serum samples were analyzed from 239 randomly selected patients treated withinterferon beta-1b, 250 μg, for at least 2 years in the Betaferon Efficacy Yielding Outcomes of a New Dose Study. EXPOSURE: Treatment with interferon beta-1b, 250 μg, for at least 2 years. MAIN OUTCOME MEASURES: Levels of IL-17F at baseline and month 6 as well as the difference between the IL-17F levels at month 6 and baseline were compared between the following: (1) patients with less disease activity vs more disease activity; (2) patients with no disease activity vs some disease activity; and (3) responders vs nonresponders. RESULTS:Levels of IL-17F measured at baseline and month 6 did not correlate with lack of response to treatment after 2 years using clinical and magnetic resonance imaging criteria. Relapses and new lesions on magnetic resonance imaging were not associated with pretreatment serum IL-17F levels. When patients with neutralizing antibodies were excluded, the results did not change. All patients with levels of IL-17F greater than 200 pg/mL were associated with poor response with some clinical or radiological activity. CONCLUSIONS AND RELEVANCE: An increase of IL-17F before and early after treatment with interferon beta-1b was not associated with poor response. These data do not support the value of IL-17F as a treatment response indicator for therapy of patients with multiple sclerosis with interferon beta, although high levels of IL-17F greater than 200 pg/mL may predict nonresponsiveness.
RCT Entities:
IMPORTANCE: High serum levels of interleukin 17F (IL-17F) at baseline have been associated with suboptimal response to interferon beta in patients with relapsing-remitting multiple sclerosis. OBJECTIVE: To further investigate the role of IL-17F in predicting treatment response to interferon beta-1b in patients with relapsing-remitting multiple sclerosis using the Singulex Erenna IL-17F immunoassay. DESIGN, SETTING, AND PATIENTS: Serum samples were analyzed from 239 randomly selected patients treated with interferon beta-1b, 250 μg, for at least 2 years in the Betaferon Efficacy Yielding Outcomes of a New Dose Study. EXPOSURE: Treatment with interferon beta-1b, 250 μg, for at least 2 years. MAIN OUTCOME MEASURES: Levels of IL-17F at baseline and month 6 as well as the difference between the IL-17F levels at month 6 and baseline were compared between the following: (1) patients with less disease activity vs more disease activity; (2) patients with no disease activity vs some disease activity; and (3) responders vs nonresponders. RESULTS: Levels of IL-17F measured at baseline and month 6 did not correlate with lack of response to treatment after 2 years using clinical and magnetic resonance imaging criteria. Relapses and new lesions on magnetic resonance imaging were not associated with pretreatment serum IL-17F levels. When patients with neutralizing antibodies were excluded, the results did not change. All patients with levels of IL-17F greater than 200 pg/mL were associated with poor response with some clinical or radiological activity. CONCLUSIONS AND RELEVANCE: An increase of IL-17F before and early after treatment with interferon beta-1b was not associated with poor response. These data do not support the value of IL-17F as a treatment response indicator for therapy of patients with multiple sclerosis with interferon beta, although high levels of IL-17F greater than 200 pg/mL may predict nonresponsiveness.
Authors: G C Ebers; K Kukay; D E Bulman; A D Sadovnick; G Rice; C Anderson; H Armstrong; K Cousin; R B Bell; W Hader; D W Paty; S Hashimoto; J Oger; P Duquette; S Warren; T Gray; P O'Connor; A Nath; A Auty; L Metz; G Francis; J E Paulseth; T J Murray; W Pryse-Phillips; R Nelson; M Freedman; D Brunet; J P Bouchard; D Hinds; N Risch Journal: Nat Genet Date: 1996-08 Impact factor: 38.330
Authors: Jordi Río; Carlos Nos; Mar Tintoré; Nieves Téllez; Ingrid Galán; Raúl Pelayo; Manuel Comabella; Xavier Montalban Journal: Ann Neurol Date: 2006-02 Impact factor: 10.422
Authors: Stefan Haak; Andrew L Croxford; Katharina Kreymborg; Frank L Heppner; Sandrine Pouly; Burkhard Becher; Ari Waisman Journal: J Clin Invest Date: 2008-12-15 Impact factor: 14.808
Authors: John Todd; Bob Freese; Ann Lu; Douglas Held; Jennifer Morey; Richard Livingston; Philippe Goix Journal: Clin Chem Date: 2007-09-21 Impact factor: 8.327
Authors: Lisa G M van Baarsen; Saskia Vosslamber; Marianne Tijssen; Josefien M C Baggen; Laura F van der Voort; Joep Killestein; Tineke C T M van der Pouw Kraan; Chris H Polman; Cornelis L Verweij Journal: PLoS One Date: 2008-04-02 Impact factor: 3.240
Authors: Saurabh Gawde; Agnieshka Agasing; Neal Bhatt; Mackenzie Toliver; Gaurav Kumar; Kaylea Massey; Andrew Nguyen; Yang Mao-Draayer; Susan Macwana; Wade DeJager; Joel M Guthridge; Gabriel Pardo; Jeffrey Dunn; Robert C Axtell Journal: Mult Scler Relat Disord Date: 2022-05-28 Impact factor: 4.808
Authors: Raquel Alenda; Lucienne Costa-Frossard; Roberto Alvarez-Lafuente; Carmen Espejo; Eulalia Rodríguez-Martín; Susana Sainz de la Maza; Noelia Villarrubia; Jordi Río; María I Domínguez-Mozo; Xavier Montalban; José C Álvarez-Cermeño; Luisa M Villar Journal: J Neurol Date: 2017-10-12 Impact factor: 4.849
Authors: Harald Hegen; Indra Adrianto; Christopher J Lessard; Alban Millonig; Antonio Bertolotto; Manuel Comabella; Gavin Giovannoni; Michael Guger; Martina Hoelzl; Michael Khalil; Franz Fazekas; Joep Killestein; Raija L P Lindberg; Simona Malucchi; Matthias Mehling; Xavier Montalban; Dagmar Rudzki; Franz Schautzer; Finn Sellebjerg; Per Soelberg Sorensen; Florian Deisenhammer; Lawrence Steinman; Robert C Axtell Journal: Neurol Neuroimmunol Neuroinflamm Date: 2016-01-27